Future CAMD Workloads and their Implications for Computer System Design IEEE 6th Annual Workshop on Workload Characterization.

Slides:



Advertisements
Similar presentations
1 Real World Chemistry Virtual discovery for the real world Joe Mernagh 19 May 2005.
Advertisements

Miroslav Brumovský28th July 2011 Miroslav Brumovský 28 th July 2011 Methods using polarization for in silico fragment-based drug design.
Knowing When to Give Up Sensible Evaluation in Virtual Screening for Drug Discovery Gwyn Skone Stephen Cameron and Irina Voiculescu.
AutoDock 4 and AutoDock Vina -Brief Intruction
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Lipinski’s rule of five
Iterative Relaxation of Constraints (IRC) Can’t solve originalCan solve relaxed PRMs sample randomly but… start goal C-obst difficult to sample points.
Jeffery Loo NLM Associate Fellow ’03 – ’05 chemicalinformaticsforlibraries.
Pop Quiz! What new technology has the United States and Japan engaged in the virtual equivalent of the space race?
FLEX* - REVIEW.
20/03/2008 Dept. of Pharmaceutics 1 APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY AND PROCESS RESEARCH Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate.
In Silico Design of Selective Estrogen Receptor Modulators from Triazoles and Imines Joey Salisbury Dr. John C. Williams Small Molecules/Large Molecules.
Protein Structure and Drug Discovery Workshop To be held at Monash University, Mebourne, Australia October 3 rd to 4 th 2006 Molecular Visualization Learn.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Important Points in Drug Design based on Bioinformatics Tools History of Drug/Vaccine development –Plants or Natural Product Plant and Natural products.
Drug discovery and development
Protein Structure Computation Gwyn Skone OUCL PRG Student Conference 2006.
Combinatorial Chemistry and Library Design
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
ClusPro: an automated docking and discrimination method for the prediction of protein complexes Stephen R. Comeau, David W.Gatchell, Sandor Vajda, and.
KISTI’s Activities on the NA4 Biomed Cluster Soonwook Hwang, Sunil Ahn, Jincheol Kim, Namgyu Kim and Sehoon Lee KISTI e-Science Division.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
CS 790 – Bioinformatics Introduction and overview.
Daniel Brown. D9.1 Discuss the use of a compound library in drug design. Traditionally, a large collection of related compounds are synthesized individually.
Business Value of SW in Drug Discovery Eric Neumann, W3C HCLSIG co-chair Teranode Corporation F2F Cambridge MA.
High-Throughput Virtual Molecular Docking: Hadoop Implementation of AutoDock4 on a Private Cloud Sally R. Ellingson Graduate Research Assistant Center.
INFSO-RI Enabling Grids for E-sciencE V. Breton, 30/08/05, seminar at SERONO Grid added value to fight malaria Vincent Breton EGEE.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
20/03/2008 Dept. of Pharmaceutics 1. Use of BIOINFORMATICS in Pharmaciutics 2  Presented By  Shafnan Nazar  Hamid Nasir 
Open source software and web services for designing therapeutic molecules G. P. S. Raghava, Head Bioinformatics Centre, Institute of Microbial Technology,
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Page 1 SCAI Dr. Marc Zimmermann Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Grid-enabled drug discovery.
It is necessary to have a quick assay for the desired biological activity and to be able to separate the bioactive compound from the other inactive substances.
1 Cheminformatics David Shiuan Department of Life Science and Institute of Biotechnology National Dong Hwa University.
STATISTICAL COMPLEXITY ANALYSIS Dr. Dmitry Nerukh Giorgos Karvounis.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
EGEE-II INFSO-RI Enabling Grids for E-sciencE WISDOM in EGEE-2, biomed meeting, 2006/04/28 WISDOM : Grid-enabled Virtual High Throughput.
1/20 Study of Highly Accurate and Fast Protein-Ligand Docking Method Based on Molecular Dynamics Reporter: Yu Lun Kuo
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA Junmei Wang,
Information Technology in the Natural Sciences Biology – Chemistry – Physics.
INFSO-RI Enabling Grids for E-sciencE EGEE Review WISDOM demonstration Vincent Bloch, Vincent Breton, Matteo Diarena, Jean Salzemann.
Histone Methyltransferases: Global Industry Report for Research Tools, Diagnostics and Drug Discovery
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine Ajay N. Jain UCSF Cancer Research Institute and Comprehensive.
WHAT IS THE IMPACT OF THE HUMAN GENOME PROJECT FOR DRUG DEVELOPMENT? Arman & Fin.
The presentation is prepared by: Andrey Voronkov, PhD – speaker (MIPT, Lomonosov Moscow State University) Vladimir Barinov – Grid Dynamics.
Docking and Virtual Screening Using the BMI cluster
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
전통적인 신약 개발 과정.
Molecular Modeling in Drug Discovery: an Overview
TIDEA Target (and Lead) Independent Drug Enhancement Algorithm.
FESR Consorzio COMETA - Progetto PI2S2 Molecular Modelling Applications Laura Giurato Gruppo di Modellistica Molecolare (Prof.
Designing Drugs Virtually P14D461P - Arni B. Hj. Morshidi P14D389P - Anisah Bt Ismail P14D397P - Syarifah Rohaya Bt Wan Idris P14D394P - Dayang Adelina.
Structural Bioinformatics Elodie Laine Master BIM-BMC Semester 3, Genomics of Microorganisms, UMR 7238, CNRS-UPMC e-documents:
Page 1 Molecular Modeling Service in Profacgen. Page 2 The three-dimensional structure of a protein provides essential information about its biological.
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Healthcare Artificial Intelligence.
Lipinski’s rule of five
Drug Discovery &Development
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Discovery and Development of Medicines
Molecular Docking Profacgen. The interactions between proteins and other molecules play important roles in various biological processes, including gene.
Bioinformatics in Drug Design
Virtual Screening.
Volume 19, Issue 1, Pages (January 2012)
Structure-based drug design: progress, results and challenges
Important Points in Drug Design based on Bioinformatics Tools
How Chemoproteomics Can Enable Drug Discovery and Development
Cheminformatics Basics
Presentation transcript:

Future CAMD Workloads and their Implications for Computer System Design IEEE 6th Annual Workshop on Workload Characterization

What is CAMD?  Computer-Assisted Molecular Discovery used in … –drug discovery –agrochemical discovery (herbicides, insecticides, etc.) –“cosmeceutical” discovery  common objectives of all CAMD applications: –find a small molecule (“drug” or “ligand” or “active”) with the right chemical structure for optimal … 1.interaction with large biomolecule (“receptor” or “target” or “protein”) 2.ADMET properties (getting & keeping ligand near receptor in body) –decide which compounds (potential drugs) should be synthesized/purchased and tested (“screened”) next? –decide by using computer to first do “virtual screening”

Molecular discovery process Genomics, Proteomics Target ID/Validation & Structure Assay Development Hits Lead Identification Preclinical/ADMET Clinical Trials Sales & Marketing Lead Optimization Cheminformatics Modeling & Simulation Decision Support CAMD Bioinformatics

Three types of CAMD problems 1.Intensive computations on one structure or complex –getting 3D structure of target from genomic information “protein folding problem” – a classic CAMD problem area parallel/distributable algorithms exist but best done on a single processor huge number of possible conformations  short cuts taken –refining 3D structure of target from X-ray/NMR data –performing protein-ligand docking & scoring virtual receptor-ligand complexation  virtual screening flexibility of ligand is currently addressed flexibility of protein is rarely addressed due to  cpu time scoring functions are crude due to  cpu time –faster cpu’s and more memory (for protein folding) would enable better quality results

Three types of CAMD problems 2.Modest computations on MANY structures –millions of real compounds; billions of “virtual cmpds” –many subtasks associated with virtual screening; e.g.: convert 2D structure of ligand to 3D (Concord) generate multiple conformations of each ligand 3D structure perform various  cpu tests to identify which ligands merit further attention using  cpu methods (e.g., docking) –crude estimates of ADMET-related properties (e.g., solubility, membrane permeability, etc.) –crude shape-complementarity tests perform docking (at increasing levels of accuracy) –large input stream  ideally suited for distributed proc. –grid-computing using many thousands of nodes (and faster nodes) would enable better quality results

Three types of CAMD problems 3.Storing data for virtual compounds –millions of real compounds; billions+ of virtual cmpnds –why store data for virtual compounds? costs time & money to generate & regenerate data –science-related reasons data generated for one project is often useful for another must store data for each conformation of each structure must store data for each structure that a compound can adopt (Optive Research will introduce technology early next year) new technology will result in HUGE volumes of virtual data –IP-related, competition-related reasons pharma industry is already planning for offensive and defensive needs in the coming virtual-screening and virtual-IP “wars” –need means to store and access huge volumes of data

Closing comments  practitioners of CAMD are well aware that quality of current methods is limited by compute-resources  rate of discovery and quality of actives discovered would both improve if CAMD methods improved  given that the sales of many actives each exceed $1 billion per year, the market for improved compute-power (and improved CAMD software) is quite substantial  I sure hope that you computer architects can help!! ;-)

Contact Info  for questions about this short presentation, please feel free to contact me at: Dr. Robert S. Pearlman, Pres. & CSO Optive Research, Inc  for questions about Optive Research, Inc. and/or about the Computer-Assisted Molecular Discovery software which we develop, contact me as indicated above or visit our web-site at: